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Background: Excessive mucin secretion in the airway is an important feature of airway inﬂammatory
diseases. MUC5AC expression is regulated by a variety of stimuli such as cytokines. Little is known about
the role of interferon (IFN)-g in MUC5AC expression in human bronchial epithelial cells.
Methods: Human pulmonary mucoepidermoid carcinoma cell line (NCI-H292) and normal human
bronchial epithelial (NHBE) cells were used to assess the effects of IFN-g on MUC5AC transcription.
Results: Transforming growth factor (TGF)-a and double-stranded RNA (polyI:C)-induced MUC5AC
mRNA and protein expression was repressed by IFN-g in a concentration-dependent manner. IFN-g
showed limited effects on TGF-a and polyI:C-induced activation of epidermal growth factor receptor
(EGFR) and extracellular signal-regulated kinase (ERK). A chromatin immunoprecipitation assay indi-
cated that Sp1 bound to its cognate sequence located on the MUC5AC promoter. The Sp1 inhibitor
mithramycin A inhibited MUC5AC mRNA expression, implying a critical role for Sp1 in MUC5AC in-
duction. Importantly, IFN-g impeded Sp1 binding to the MUC5AC promoter.
Conclusions: These results suggest that IFN-g represses MUC5AC expression, disturbing binding of Sp1 to
its target sequences.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Mucus production by bronchial epithelial cells plays an impor-
tant role in the clearance of pathogens from the lungs. However,
excessive secretion of mucus in some disease states can generate
mucus plugs, leading to impaired respiration and possibly, death.1,2
Therefore, ﬁne control of mucus secretion is important for the
physiological functions of the airways.
MUC5AC, which is secreted mainly from goblet cells, is a major
component of airway mucins.3 MUC5AC is upregulated in response
to inﬂammation of the lungs caused by disorders such as bronchialGraduate School of Medicine,
Gunma 371-8511, Japan.
wa).
ety of Allergology.
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are induced by pro-inﬂammatory cytokines such as interleukin (IL)-
4, IL-13, and transforming growth factor (TGF)-a,5 and by external
agents such as viruses and cigarette smoke. In inﬂamed tissues,
different stimuli can function simultaneously in the same locale
while having diverse and interacting functions. Some costimuli
initiate common effects, whereas others negatively regulate or
synergizewith each other. polyI:C, amimic of viral double-stranded
RNA, has been observed to enhance the effects of TGF-a, a ligand for
the epidermal growth factor receptor (EGFR).6 These two stimuli
synergistically induce the production of MUC5AC. An underlying
mechanism for this synergism is that polyI:C suppresses the
expression of dual speciﬁcity phosphatase 6 (DUSP6), a negative
regulator of extracellular signal-regulated kinase (ERK)1/2, which
augments MAPK signaling pathways that are required for MUC5AC
expression.6 As another example, CCL20 has also been shown tovier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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G protein-coupled receptor, CCR6.7
Interferon (IFN)- g is a pro-inﬂammatory multi-functional
cytokine produced by cells involved in Type 1 immunity, such as
innate lymphoid cells, natural killer cells, CD8þ cytotoxic T cells,
and CD4þ T helper 1 (Th1) cells.8e10 IFN-g activates macrophages,
converting them to potent effector cells during infection of intra-
cellular microbes, and it antagonizes the functions of T helper 2
(Th2) cell cytokines such as IL-4 and IL-13.11 IFN-g levels are usually
decreased in individuals with bronchial asthma but increased in
severe asthma.12 After infection with respiratory syncytial virus,
mice deﬁcient in the IFN-g receptor show severe airway inﬂam-
mation as indicated by damaged epithelial cells and excessive
mucus production.13,14 These ﬁndings suggest that IFN-g plays a
vital role in host defenses against viral infections and in the sup-
pression of airway mucus production. However, little is known
about the mechanisms by which IFN-g suppresses mucin
production.
We explored the roles of IFN-g in mucin production, speciﬁcally
MUC5AC transcription in human bronchial epithelial cells.
Methods
Cell culture and stimulation
The human pulmonary mucoepidermoid carcinoma cell line
NCI-H292 was maintained in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and
streptomycin (100 mg/ml) at 37 C in a humidiﬁed atmosphere with
5% (v/v) CO2. Cells were grown until 80% conﬂuence and kept in
serum-free RPMI 1640 medium for 6 h before stimulation. Normal
human bronchial epithelial (NHBE) cells were purchased from
Lonza (Basel, Switzerland). NHBE cells were seeded at a density of
1.3  105/cm2 into 12-well plates containing bronchial epithelial
growth medium (Lonza) supplemented with deﬁned growth fac-
tors and retinoic acid from the SingleQuot kit (Lonza), and were
incubated at 37 C in a humidiﬁed atmosphere with 5% CO2. The
cells were exposed to 25 mg/ml polyI:C (SigmaeAldrich, St. Louis,
MO, USA) and 4 ng/ml TGF-a (R&D Systems, Minneapolis, MN,
USA). IFN-g (R&D Systems) was added at 30 ng/ml, unless other-
wise indicated, simultaneously with polyI:C and TGF-a. Mithra-
mycin A (Cayman chemical, Orland, FL, USA) was added 30 min
prior to TGF-a and polyI:C stimulation.
Gene knockdown with short interfering RNA (siRNA)
siRNAs against Janus kinase 1 (JAK1) and signal transducers and
activators of transcription-1 (STAT1) were used together with
control scrambled siRNA (Life Technologies, Carlsbad, CA, USA).
Two different siRNAs for each gene were used (s277 and s279 for
STAT1, s7646 and s7647 for JAK1) to avoid off-target effects of RNA
interference. NCI-H292 cells were seeded into 6-well plates and
cultured to 50% conﬂuence. The cells were transfected with 50 nM
siRNA with 5 ml of Lipofectamine RNAiMAX (Life Technologies) and
kept in RPMI with 10% FBS without antibiotics for 24 h. Then, the
mediumwas changed to serum-free RPMI 1640. After 12 h, the cells
were treated with IFN-g and polyI:C, and/or TGF-a for 12 h.
Quantitative reverse transcription polymerase chain reaction
(qRT-PCR) analysis
Total RNA was isolated using the ToTally RNA kit (Life Technol-
ogies). Reverse transcription was performed with 1 mg of total RNA
and oligo (dT) primers using SuperScript III (Life Technologies) ac-
cording to the manufacturer's protocol. Relative mRNA levels werequantiﬁed with either SYBR Green or TaqMan gene expression as-
says (Life Technologies) on an ABI Prism 7900HT sequence detection
system. Initial denaturation was performed at 95 C for 10 min,
followed by 40 cycles of denaturation at 95 C for 15 s, and annealing
and extension at 60 C for 1 min. The threshold cycle time (CT) was
recorded for each sample to reﬂect the level of mRNA expression. A
validation experiment in a given sample at different RNA concen-
trations conﬁrmed linear dependence of the CT value on the con-
centrations of the genes of interest and GAPDH, and the consistency
of DCT. DDCT was used for relative mRNA quantitation.
The following primers of TaqMan gene expression assays
(Life Technologies) were used; MUC5AC (HS01365601_m1), JAK1
(HS00233820_m1), STAT1 (HS01014002_m1), and GAPDH
(4326317E). The following primers were used for SYBRGreen assays;
SP1, forward (50-ACCAAGCTGAGCTCCATGAT-30), and reverse (50-
CCTCAGTGCATTGGGTACTTC-30); GAPDH (50- GCACCGTCAAGGCT-
GAGAAC-30) and reverse (50- TGGTGAAGACGCCAGTGGA-30).
Western blot analysis
Cells (3.0  105) were washed with PBS and lysed in 300 ml of
lysis buffer [0.5% NP-40,10mM TriseCl, pH 7.4, 150mMNaCl, 3 mM
p-amidinophenylmethanesulfonyl ﬂuoride (SigmaeAldrich), 5 mg/
ml aprotinin (SigmaeAldrich), 2 mM sodium orthovanadate (Sig-
maeAldrich), and 5 mM EDTA]. Whole cell extracts were subjected
to electrophoresis on 7.5e12% Triseglycine gels (XVPantera Gel;
DRC, Tokyo, Japan) and then transferred to polyvinylidene diﬂuor-
ide membranes (Immobilon-P; Millipore, Bedford, MA, USA).
Membranes were blocked with 5% skimmilk in Tris-buffered saline
with 0.05% Tween-20 (TBS-T, pH 7.5) for 30 min at room temper-
ature (RT) and probed with primary anti-human phosphor-p44/42
(Thr202/Tyr204) (D13.14.4E), p44/42 MAP kinase antibodies
(137F5), anti-EGF Receptor (D38B1), anti-phospho-EGF Receptor
(Tyr1068) (D7A5), anti-SP1 (D4C3) (all from Cell Signaling Tech-
nology Inc., Beverly, MA, USA), and anti-DUSP6 (ab76310; Abcam,
Cambridge, UK) antibodies for 1 h at RT. Then, themembranes were
washed with TBS-T and incubated with a secondary donkey anti-
rabbit immunoglobulin antibody conjugated to horseradish
peroxidase (HRP) (GE Healthcare, Tokyo, Japan) for 1 h at RT. Pro-
teins were detected using a chemiluminescence detection system
according to themanufacturer's instructions (ECL PlusWestern Blot
Detection System; GE Healthcare).
Flow cytometry
Cells were collected using trypsin with 0.05% EDTA and ﬁxed
with 4% paraformaldehyde for 15 min. The cells were washed with
FACS buffer [3% FBS, 0.05% NaN3 in phosphate-buffered saline
(PBS)] and blocked with blocking buffer (0.1% Triton-X 100, 3%
bovine serum albumin in PBS) for 15 min. Then, the cells were
incubated with mouse anti-MUC5AC antibody (45M1; Abcam)
diluted at 1:200 in FACS buffer for 30 min. After washing with FACS
buffer, the cells were incubated for 30 min with Alexa 488-
conjugated anti-mouse IgG antibody (Life Technologies) diluted at
1:400 in FACS buffer. The cells were washed with FACS buffer and
subjected to ﬂow cytometric analysis using a BD FACSAria II (BD
Bioscience, Franklin Lakes, NJ, USA).
Enzyme-linked immunoassay (EIA)
MUC5AC protein was measured with EIA as described previ-
ously.6 Brieﬂy, 50 ml of culture was collected at 12 h after stimula-
tion and incubated overnight with bicarbonate-carbonate buffer
(50 ml) at 40 C in a 96-well plate (Nunc Labware Products/Sigma-
eAldrich). The plates were washed with PBS and blocked with 2%
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monoclonal anti-MUC5AC antibody (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) diluted 1:100 with PBS containing 0.05%
Tween-20 was added for 1 h. HRP-conjugated sheep anti-mouse
IgG antibody (1:10,000) (GE Healthcare) was used as a secondary
antibody. Color was developed with 3,30,5,50-tetramethylbenzidine
peroxidase solution (KPL, Gaithersburg, MD, USA) and the reaction
was stopped with 1 M H2SO4. The data were read by using Wallc
ARVO SX (PerkinElmer, Waltham, MA, USA).
Chromatin immunoprecipitation (ChIP)
ChIP analysis was performed as described previously.15 Cells
were ﬁxed with 1% formalin in PBS for 10 min at room temperature
and incubated with 0.125 M glycine for 5 min for quenching. The
cells were collected and centrifuged after washing three times with
PBS. Pellets were suspended in swelling buffer (25 mMHepes, pH 8,
1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40, 1 mM DTT, 1  protease in-
hibitor cocktail (Nacalai Tesque, Kyoto, Japan), incubated on ice for
10 min, and centrifuged. The pellets were homogenized with plastic
homogenizers. The cells were sonicated in sonication buffer (50 mM
Hepes pH 8, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-
deoxycholate, 0.1% SDS, protease inhibitor cocktail). Chromatin
was sonicated with a Bioruptor (Cosmo Bio, Tokyo, Japan) and the
soluble fraction of chromatin was incubated with mouse anti-SP1
antibody (SC-59; Santa Cruz Biotechnology, Dallas, TX, USA) over-
night at 4 C. Antibody-conjugated chromatin was collected with
40 mL of Dynabeads conjugated with anti-mouse antibody (Life
Technologies) by rotating for 1 h at 4 C. The beads were washed
with low-salt (20 mM TriseHCl pH 8, 150 mM NaCl, 2 mM EDTA, 1%
Triton X-100, 0.1% SDS), high-salt (20 mM TriseHCl pH 8, 500 mM
NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), and LiCl (10 mM Tris
pH 8.0, 1 mM EDTA, 250 mM LiCl, 1% NP-40, 1% Na-deoxycholate)
buffers for 5 min each, then washed twice with TriseEDTA for
3 min. Immunoprecipitates were collected by incubation with
elution buffer (1% SDS, 100 mM NaHCO3)s for 15 min at 65 C twice,
treated with RNase and proteinase K, and puriﬁed. Coimmunopre-
cipitated DNA was detected by qPCR as described above using the
following primers: CS-UP, forward (50-CTGGCTGAGGGAGGAGAAA-
30) and reverse (50-AGTGCCCCCTGCGTGTCT-30); CS-DN, forward (50-
CCCACTGCCTCCTGTCTATC-30) and reverse (50- GCATAGGGAAGG
GCTTGAG-30); CS-Int, forward (50-AGCAGCATAGCCCCTGACT-30) and
reverse (50-CCCGAGATCTGAGCTCCTAC-30); DUSP-UP, forward (50-
TCATGACGTTGGCATTTCTG-30) and reverse (50- GGGAAACAAGG
TACCGTCAA-30); and DUSP-Exn, forward (50- CGTCCTTGAGCTTCTT-
GAGC-30) and reverse (50- ACAGTGGTGCTCTACGACGA-30).
Statistical analysis
All data are expressed as the mean ± SD. Results were analyzed
using one-way ANOVA followed by a post-hoc Tukey multiple
comparison test (Fig. 1A, B), ManneWhitney test (Fig. 1E, 2) or
KruskaleWallis test (Fig. 5B). Analyses were performed with the
GraphPad Prism software version 5.04 and p < 0.05 was considered
signiﬁcant.
Results
IFN-g decreases the expression of MUC5AC mRNA
Because IFN-g plays a role in viral infections and allergic
inﬂammation, and in both conditions mucus secretion from the
airway is increased, we studied how IFN-g inﬂuences mucin pro-
duction from human bronchial epithelial cells. A combination of
TGF-a and polyI:C (hereafter designated as “TP”) was used based onour previous data showing that this combination robustly induces
MUC5AC mRNA expression in NHBE and NCI-H292 cells.6 As ex-
pected, TP stimulation signiﬁcantly increased MUC5AC mRNA
expression (Fig. 1A). Simultaneous addition of IFN-g repressed the
induction ofMUC5AC in NHBE (Fig. 1A). The inhibition by IFN-gwas
also observed in NCI-H292 cells (Fig. 1B). Immunocytochemistry for
cytosolic MUC5AC proteins revealed that IFN-g also reduced the TP-
induced expression of the MUC5AC protein in the cytoplasm
(Fig. 1C). The number of cells expressing MUC5AC was markedly
reduced by IFN-g (Fig. 1D). MUC5AC is released upon a variety of
stimuli.5,6,16 The amount of MUC5AC in cellular secretion was
determined by EIA. IFN-g reduced the amount of secreted MUC5AC
protein (Fig. 1E). Although IFN-g triggers apoptosis in some cell
types,17 cells with condensed nuclei were not increased as judged
by immunostaining and ﬂow cytometric analysis (data not shown).
Taken together, these results indicated that both mRNA and protein
expression as well as release of MUC5AC can be repressed by IFN-g.
The JAK/STAT pathway is essential for IFN-g to decrease MUC5AC
mRNA expression
IFN-g binds to receptors on the cell surface to activate JAK1.
Activated JAK1 phosphorylates STAT1, which then dimerizes,
translocates to the nucleus, and binds to its cognate sequence to
induce target gene transcription.18 To determine whether JAK1 and
STAT1 are involved in the IFN-g-mediated suppression of TP-
induced MUC5AC expression, knockdown experiments were per-
formed by introducing JAK1 and STAT1 siRNA into cells. The siRNAs
reduced the expression of both JAK1 and STAT1 (Supplementary
Fig. 1). Next, we stimulated these cells with TP in the presence or
absence of IFN-g. MUC5AC expression was signiﬁcantly repressed
in the presence of IFN-g in control RNAi (Fig. 2). The suppression
was attenuatedwhen either JAK1 or STAT1were silenced, andmore
profoundly so when both were silenced simultaneously (Fig. 2).
This indicated that IFN-g uses the JAK/STAT pathway to inhibit the
transcription of MUC5AC.
IFN-g partially inhibits the prolonged activation of EGFR and ERK1/2
induced by TGF-a and polyI:C
TGF-a binds to EGFR to transduce its signals into cells. Upon
extracellular ligand binding, EGFR is dimerized and autophos-
phorylates multiple tyrosine residues positioned on its intracellular
domain. EGFR was phosphorylated on tyrosine residue Y1068 by
stimulation with TP in H292 cells (Fig. 3A). The phosphorylation
was detectable until 12 h after stimulation. It appeared to be
slightly, albeit insigniﬁcantly, suppressed at later time points in the
presence of IFN-g as compared to in the absence thereof (Fig. 3A).
A previous study demonstrated that the MAPK pathway is vital
for the induction of MUC5AC expression by TGF-a.5 We also have
shown that the MEK inhibitor U0126 strongly inhibits MUC5AC
expression caused by stimulation with TP,6 which prompted us to
study how IFN-g inﬂuences the activation of the MAPK signaling
pathway. ERK1/2 was activated by TP stimulation. The phosphor-
ylation gradually decreased, but was still signiﬁcantly elevated
even 12 h after stimulation (Fig. 3B). Simultaneous supplementa-
tion with IFN-g did not reduce ERK phosphorylation from 3 to 12 h
(Fig. 3B). Several negative regulators of the MAPK pathways,19
including DUSP6, an ERK-speciﬁc phosphatase, are known. We
have previously shown that reduction of DUSP6 expression by
polyI:C underlies the synergistic induction of MUC5AC expression
by stimulationwith TP. We evaluated whether DUSP6 is involved in
the reduction of phosphorylation of ERK observed at later time
points. Western blot analysis showed that stimulation with TP
markedly reduced DUSP6 protein expression as compared to the
Fig. 1. IFN-g decreases the expression of MUC5AC. (A)MUC5AC mRNA expression in NHBE cells. qRT-PCR was performed forMUC5AC mRNA with NHBE cells treated with or without
30 ng/mL of IFN-g at the indicated concentrations in the presence of TGF-a or polyI:C, or both. Data were normalized to the control (without any stimulation). *p < 0.05 one-way
ANOVA with Tukey's post-test (n ¼ 6). (B) MUC5AC mRNA expression in NCI-H292 cells. qRT-PCR was performed for MUC5AC mRNA with H292 cells treated with IFN-g at the
indicated concentrations in the presence of TGF-a and polyI:C. Data were normalized to the control (without any stimulation). ***p < 0.001 one-way ANOVA with Tukey's post-test
(n ¼ 7). (C) Representative images of immunostaining for cytoplasmic MUC5AC in H292 cells stimulated with TGF-a and polyI:C with (TPI) or without IFN-g (TP) for 12 h. (D) Flow-
cytometric analysis ofMUC5AC expression. Cells were stimulated with TP or TPI for 12 h, ﬁxed, and stained with an anti-MUC5AC antibody and then with FITC-conjugated anti-mouse
IgG secondary antibody. The numbers of MUC5AC-positive cells were determined by ﬂow cytometry. (E) Quantitation of MUC5AC protein secreted into the culture media. The amount
of MUC5AC was determined with enzyme-linked immunoassay (EIA). Data were normalized to the control (without any stimulation). *p < 0.05 with ManneWhitney test. n ¼ 6.
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Fig. 2. Effects of RNAi for JAK1 and/or STAT1 on the expression of MUC5AC. Cells were
transfected with siJAK1 and/or siSTAT1 and stimulated with TGF-a and polyI:C with or
without IFN-g for 12 h in the presence or absence of IFN-g. MUC5AC mRNA expression
was determined by qRT-PCR and was normalized to GAPDH mRNA. #1 and #2 indicate
different combinations of siRNA probes for STAT1 and JAK1; #1 for IDs: s277 and
s7646, #2 for s279 and s7647, respectively. The signiﬁcant suppression of MUC5AC
mRNA by IFN-g was most signiﬁcantly prevented by treatment with a combination of
siJAK1 and si-STAT1. Data were analyzed with a ManneWhitney test (n ¼ 6e12).
Fig. 3. Effects of IFN-g on EGFR and ERK phosphorylation. Cells were stimulated with
TGF-a and polyI:C with (TPI) or without IFN-g (TP) for the indicated times and subjected
to western blotting. Representative results are shown. (A) Phosphorylation of EGFR at
Y1068 after stimulation for 1e12 h. Whole cell lysates were subjected to western
blotting using anti-EGFR and anti-phospho-EGFR (Y1068) antibodies. Band intensities of
phospho-EGFR (pEGFR) and EGFR in the repeated experiments (n ¼ 7) were quantiﬁed.
(B) Phosphorylation of ERK1/2 after stimulation for 1e12 h. Anti-ERKs and anti-
phospho-EKRs (pERK) antibodies were used. Band intensities of pEGFR and EGFR in
the repeated experiments (n ¼ 7) were quantiﬁed. (C) DUSP6 protein expression. Cells
were stimulated with TGF-a and polyI:C with (TPI) or without IFN-g (TP) for the indi-
cated times and subjected to western blotting. Anti-DUSP6 antibody was used.
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tions.6 Contrary to our expectation, however, IFN-g did not
ameliorate the reduced DUSP6 expression (Fig. 3C). These results
indicated that IFN-g did not strongly inhibit activation of either
EGFR or EKR, or induce DUSP6 expression, suggesting that IFN-g
represses MUC5AC expression through other mechanisms.
Reduced binding of Sp1 to the MUC5AC promoter is involved in the
inhibitory effects of IFN-g
MUC5AC is induced in human bronchial epithelial cells by awide
variety of stimuli including cigarette smoke and viral infection, in
addition to EGFR stimulation by cytokines. Several transcription
factors such as NF-kB and Sp1 play pivotal roles in MUC5AC
expression in response to such stimuli. We have previously shown
that NF-kB plays a limited role in TP-induced expression of
MUC5AC.6,20 Therefore, we aimed to determine whether Sp1 par-
ticipates in the transcriptional activation of MUC5AC by TP.
Mithramycin A, a speciﬁc inhibitor of Sp1 binding to DNA, inhibited
TP-induced MUC5AC expression in a concentration-dependent
manner (Fig. 4), which indicates that Sp1 plays a crucial role in
MUC5AC expression in response to stimulation with TP.
There are two consensus Sp1 binding sites located at the 30
upstream region of the transcription start site of MUC5AC (Fig. 5A).
One of these binding sites was previously shown to be of para-
mount importance in cigarette smoke-induced expression of
MUC5AC by a promoter assay.21 Hence, we investigated which
consensus binding sites are occupied by Sp1 after stimulation with
TP. The ChIP assay revealed that Sp1 binds to a consensus binding
site located ~3.5 kb upstream of the transcriptional start site of
MUC5AC (CS-DN), but does not bind to the ~3.7 kb upstream site
(CS-UP) (Fig. 5A, B). A consensus Sp1 binding site within the ﬁrst
intron (CS-Int) and negative control sequences of the promoter
(DUSP-UP) and the ﬁrst exon (DUSP-Exn) of DUSP6were not bound
by Sp1. Furthermore, binding of Sp1 to CS-DN was decreased to
control levels by treatment with IFN-g. Because in a cigarette
smoke model, an increase in SP1 binding to the MUC5AC promoter
was dependent on an increase in SP1 synthesis,21 we checked the
expression level of SP1 after IFN-g stimulation. SP1 mRNA expres-
sion 3 h after TP stimulation, which was the same period as thatFig. 4. The role of SP1 in IFN-g-mediated repression ofMUC5AC expression. A. Effect of
mithramycin A, an SP1 inhibitor, on TGF-a- and polyI:C-induced MUC5AC mRNA
expression. Cells were treated with mithramycin A for 30 min before stimulation at the
indicated concentrations. MUC5AC expression was determined with qRT-PCR (n ¼ 3).
Fig. 5. Sp1 binding to MUC5AC promoter was inhibited by IFN-g. (A) Schematic representation of the MUC5AC gene. Consensus binding sites for SP1 at 3.7 (CS-UP) and 3.5 kb
(CS-DN) upstream of the transcription start site and at the ﬁrst intron (CS-Int) are indicated. (B) ChIP for SP1 at the site indicated in A and negative control sequences on the
promoter (DUSP-UP) and exon 1 (DUSP-Exn) sites of DUSP6. **p < 0.01; KruskaleWallis test (n ¼ 9). (C) qRT-PCR analysis of SP1 expression after TGF-a and polyI:C stimulation with
(TPI) or without IFN-g (TP) (n ¼ 6). (D)Western blot for SP1 expression with TP or TPI stimulation for the indicated periods. (E) Quantitation of blot intensities at 3 h after TP or TPI
stimulation (n ¼ 5).
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IFN-g (Fig. 5C). SP1 protein increased in a time-dependent manner
after TP or TPI stimulation and appeared to decrease 12 h later in
the presence of IFN-g (Fig. 5D). However, 3 h after stimulation, the
protein amount was hardly affected by IFN-g (Fig. 5E). This in-
dicates that a decrease in SP1 binding to the MUC5AC promoter
observed with ChIP assay (Fig. 5B) is not due to a reduction of SP1
expression. Taken together, these results demonstrated speciﬁc
binding of Sp1 to the promoter of MUC5AC and the inhibition
thereof by IFN-g, and suggest that IFN-g inhibits MUC5ACtranscription at least in part by impeding Sp1 from binding to one
of its cognate sequences on the MUC5AC promoter.
Discussion
Mucus secretion is one of the most important defense systems
to eliminate pathogens or allergens from the airway epithe-
lium.22,23 Roy et al.22 showed that a lack of MUC5AC had little effect
on the clearance of bacteria from the airways, whereas a lack of
MUC5B delayed pathogen clearance. However, overexpression of
T. Oyanagi et al. / Allergology International 66 (2017) 75e82 81MUC5AC in the airways increased the clearance of pathogens,24
indicating that secretion of this mucin into the airways protects
against infection. In contrast, mucin hypersecretion from bronchial
epithelial cells can cause airﬂow obstruction in inﬂammatory
airway diseases such as bronchial asthma, and in bacterial or viral
infections. Therefore, ﬁne control of mucin production, or a balance
between positive and negative regulation of mucin expression, is of
great importance in maintaining airway homeostasis.
IFN-g is a pro-inﬂammatory, multifunctional cytokine that is
produced by Type 1 innate lymphoid cells, natural killer cells, CD8þ
cytotoxic T cells, and Th1 cells.8e10 IFN-g suppressed mucus pro-
duction in a murine airway allergy model.25 Transplantation of
allergen-sensitized Th1 cells into airway allergy model mice sup-
pressed eosinophil inﬁltration, mucus production in the airways,
and production of antigen-speciﬁc IgE.25 Furthermore, in mice
lacking the IFN-g receptor, some of the effects achieved by trans-
plantation of antigen-sensitized Th1 cells, including mucus pro-
duction, disappeared. In the current study, we demonstrated that
IFN-g suppresses mucin production in human airway epithelium
cells by inhibiting transcription of the MUC5AC gene, which was
induced by other stimuli.
EGFR was activated by prolonged (12 h) phosphorylation of
Y1068 in response to TGF-a and polyI:C (Fig. 3A). Such prolonged
phosphorylationwas slightly repressed by IFN-g (Fig. 3A). IFN-g has
diverse inﬂuences on EGFR activation. For example, Burova et al.26
reported that IFN-g induced transactivation of EGFR in A431 and
HeLa cells. In contrast, IFN-g was shown to inhibit EGFR activation,
speciﬁcally phosphorylation of Y1068, in colonocytes.27 Further-
more, in a melanoma cell line, IFN-g reduced the cell surface
expression of EGFR protein.28 These variable responses might be
explained by differences in the cell types used, the differentiation
status of the cells, or the experimental conditions. The mechanisms
underlying these diverse functions of IFN-g remain to be
elucidated.
We observed that IFN-g did not suppress phosphorylation of the
MAPK signaling molecules ERK1/2 at later time points. ERK1/2 is
activated by IFN-g in macrophages23 and inhibited in thyroid
cells.29 The different effects of IFN-g between other studies and
ours likely reﬂect the pleiotropic and context-dependent nature of
IFN-g functions.
In addition to EGFR and MAPK, we focused on the transcription
factor SP1, which has been implicated in MUC5AC gene expression
induced by a wide variety of stimuli in bronchial epithelial cells.21
TP-induced Sp1 binding to the MUC5AC promoter was almost
abolished by IFN-g. We concluded that inhibition of Sp1 binding to
the MUC5AC promoter by IFN-g participates in the inhibition of
MUC5AC expression.
IFN-g is a well-conserved and widely distributed cytokine that
plays a central role in cellular immunity.11 The most prominent and
well-characterized function of IFN-g released from Th1 cells is to
suppress inﬂammatory responses mediated by Th2 cell-derived
cytokines such as IL-4 and IL-13. These activities of IFN-g are
mediated primarily through the activation of JAK kinases and STAT,
a latent transcription factor, by inducing expression of genes
through the binding of STATs to gamma activating sequences on
their promoters. However, a previous study showed that IFN-g can
also repress gene expression30 through as-yet unknown mecha-
nisms. Intriguingly, Trilling et al.30 performed a microarray-based
analysis of genes that were up- or downregulated without pro-
tein synthesis by IFN-g in NIH-3T3 ﬁbroblasts, and found that genes
downregulated by IFN-g showed signiﬁcant enrichment of GC-box
and Sp1 binding sequences in their regulatory regions. This
observation is consistent with our current ﬁnding that IFN-g in-
hibits the expression of MUC5AC through the release of Sp1 from
the MUC5AC promoter. Because we used different cells than thoseused by Trilling et al., the similar results suggest that the suppres-
sion of Sp1-induced gene expression by IFN-g is a general rather
than a cell-type-speciﬁc phenomenon.
In conclusion, the mechanisms underlying MUC5AC transcrip-
tional inhibition by IFN-g though the release of Sp1 remains largely
unknown. Nevertheless, we conclude that IFN-g is a negative
regulator of MUC5AC production from human bronchial epithelial
cells at the transcriptional level.
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